Pharmacokinetic Study for PCA Derivate Formulations (PCA 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00729729
Recruitment Status : Completed
First Posted : August 7, 2008
Last Update Posted : August 28, 2012
Information provided by:
Hadassah Medical Organization

Brief Summary:
A comparative bioavailability study of PCA slow release versus immediate release formulations, after a single dose to fasting healthy subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: PCA Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: Phase 4, Three Way Cross-over, Pharmacokinetic Study for PCA Derivate Formulations in Healthy Subjects
Study Start Date : July 2008
Actual Primary Completion Date : February 2009
Actual Study Completion Date : December 2009

Arm Intervention/treatment
Placebo Comparator: 1
Drug: PCA
Placebo tablet, once
Experimental: 2
Slow release PCA derivative
Drug: PCA
PO, 700mg, once
Experimental: 3
Slow release PCA derivative higher dose
Drug: PCA
PO, 1000mg, once

Primary Outcome Measures :
  1. PCA derivate blood levels [ Time Frame: 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects who have completed the informed consent process culminating with written informed consent by the subject.
  • Males
  • Age 18-45 years
  • Abstinence from alcohol for 1 week prior to the study
  • Non smoking
  • BMI > 19 and < 30
  • No history or evidence of significant

    • cardiovascular,
    • hepatic,
    • renal,
    • hematopoietic,
    • gastrointestinal disease,
    • endocrine,
    • metabolic,
    • psychiatric
    • psychological disorders
  • Normal physical examination
  • Within +/- 10% of normal values in laboratory examinations

Exclusion Criteria:

  • Subjects who suffer from a current medical condition.
  • Subjects who smoke.
  • Subjects who drink > 20 grams of alcohol per day.
  • Subjects who take prescription medication.
  • Subjects with an abnormality in screening blood tests
  • Known sensitivity to any ingredients in the study drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00729729

Hadassah Medical Organization
Jerusalem, Israel, 91120
Sponsors and Collaborators
Hadassah Medical Organization

Responsible Party: Gadi Lalazar MD, Hadassah Medical Organization Identifier: NCT00729729     History of Changes
Other Study ID Numbers: PCA pharmacokinetics 1
First Posted: August 7, 2008    Key Record Dates
Last Update Posted: August 28, 2012
Last Verified: August 2008

Keywords provided by Hadassah Medical Organization:
of PCA